Barclays PLC Reports New 5.96% Stake in Reviva Pharmaceuticals Holdings

On May 14, 2026, Barclays PLC filed a Schedule 13G with the SEC, reporting a new significant ownership stake in Reviva Pharmaceuticals Holdings, Inc. (ticker: RVPHW). As of the event date on March 31, 2026, Barclays PLC beneficially owns 763,579 shares of common stock, representing a 5.96% ownership interest in the company. This filing marks an increase from a previously reported 0.0% position, establishing Barclays PLC as a major institutional holder. The filing indicates that the shares are held by Barclays PLC in its capacity as a parent holding company, with Barclays Bank PLC identified as the relevant subsidiary. According to the filing certifications, these securities were acquired in the ordinary course of business and are not held for the purpose of influencing or changing the control of the issuer. Barclays PLC exercises sole voting and dispositive power over the entirety of the reported shares. The reporting person is based in London, UK, and the issuer is headquartered in Cupertino, California.